Detalhe da pesquisa
1.
Novel variants in GALE cause syndromic macrothrombocytopenia by disrupting glycosylation and thrombopoiesis.
Blood
; 141(4): 406-421, 2023 01 26.
Artigo
Inglês
| MEDLINE | ID: mdl-36395340
2.
Chemotherapy or allogeneic transplantation in high-risk Philadelphia chromosome-negative adult lymphoblastic leukemia.
Blood
; 137(14): 1879-1894, 2021 04 08.
Artigo
Inglês
| MEDLINE | ID: mdl-33150388
3.
Use of eltrombopag for patients 65 years old or older with immune thrombocytopenia.
Eur J Haematol
; 104(3): 259-270, 2020 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-31840311
4.
Eltrombopag safety and efficacy for primary chronic immune thrombocytopenia in clinical practice.
Eur J Haematol
; 97(3): 297-302, 2016 Sep.
Artigo
Inglês
| MEDLINE | ID: mdl-26709028
5.
Successful discontinuation of eltrombopag after complete remission in patients with primary immune thrombocytopenia.
Am J Hematol
; 90(3): E40-3, 2015 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-25400215
6.
Do chronic myeloid leukemia patients with late "warning" responses benefit from "watch and wait" or switching therapy to a second generation tyrosine kinase inhibitor?
Am J Hematol
; 89(11): E206-11, 2014 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-25059397
7.
Romidepsin Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone Versus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Final Analysis of the Ro-CHOP Trial.
J Clin Oncol
; 42(14): 1612-1618, 2024 May 10.
Artigo
Inglês
| MEDLINE | ID: mdl-38364196
8.
Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA).
J Clin Oncol
; 40(3): 242-251, 2022 01 20.
Artigo
Inglês
| MEDLINE | ID: mdl-34843406
9.
R-COMP versus R-CHOP as first-line therapy for diffuse large B-cell lymphoma in patients ≥60 years: Results of a randomized phase 2 study from the Spanish GELTAMO group.
Cancer Med
; 10(4): 1314-1326, 2021 02.
Artigo
Inglês
| MEDLINE | ID: mdl-33492774
10.
Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients.
Haematologica
; 95(5): 745-51, 2010 May.
Artigo
Inglês
| MEDLINE | ID: mdl-20133893
11.
Results of an Early Access Treatment Protocol of Daratumumab Monotherapy in Spanish Patients With Relapsed or Refractory Multiple Myeloma.
Hemasphere
; 4(3): e380, 2020 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-32647799
12.
Neurological Comorbidity Is a Predictor of Death in Covid-19 Disease: A Cohort Study on 576 Patients.
Front Neurol
; 11: 781, 2020.
Artigo
Inglês
| MEDLINE | ID: mdl-32733373
13.
The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia.
Haematologica
; 93(12): 1797-805, 2008 Dec.
Artigo
Inglês
| MEDLINE | ID: mdl-18815192
14.
Efficacy and safety of native versus pegylated Escherichia coli asparaginase for treatment of adults with high-risk, Philadelphia chromosome-negative acute lymphoblastic leukemia.
Leuk Lymphoma
; 59(7): 1634-1643, 2018 07.
Artigo
Inglês
| MEDLINE | ID: mdl-29165013
15.
Is intracranial pressure monitoring in the epidural space reliable? Fact and fiction.
J Neurosurg
; 106(4): 548-56, 2007 Apr.
Artigo
Inglês
| MEDLINE | ID: mdl-17432703
16.
The number of tumor infiltrating T-cell subsets in lymph nodes from patients with Hodgkin lymphoma is associated with the outcome after first line ABVD therapy.
Leuk Lymphoma
; 58(5): 1144-1152, 2017 05.
Artigo
Inglês
| MEDLINE | ID: mdl-27733075
17.
HLA specificities are associated with prognosis in IGHV-mutated CLL-like high-count monoclonal B cell lymphocytosis.
PLoS One
; 12(3): e0172978, 2017.
Artigo
Inglês
| MEDLINE | ID: mdl-28249016
18.
Efficacy and safety of eltrombopag in persistent and newly diagnosed ITP in clinical practice.
Int J Hematol
; 106(4): 508-516, 2017 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-28667351
19.
Experimental and clinical regenerative capability of human bone marrow cells after myocardial infarction.
Circ Res
; 95(7): 742-8, 2004 Oct 01.
Artigo
Inglês
| MEDLINE | ID: mdl-15358665
20.
Switching to second-generation tyrosine kinase inhibitor improves the response and outcome of frontline imatinib-treated patients with chronic myeloid leukemia with more than 10% of BCR-ABL/ABL ratio at 3 months.
Cancer Med
; 4(7): 995-1002, 2015 Jul.
Artigo
Inglês
| MEDLINE | ID: mdl-25756742